201 related articles for article (PubMed ID: 29231244)
1. SIRT7 depletion inhibits cell proliferation, migration, and increases drug sensitivity by activating p38MAPK in breast cancer cells.
Chen KL; Li L; Yang FX; Li CM; Wang YR; Wang GL
J Cell Physiol; 2018 Sep; 233(9):6767-6778. PubMed ID: 29231244
[TBL] [Abstract][Full Text] [Related]
2. SIRT7 depletion inhibits cell proliferation and androgen-induced autophagy by suppressing the AR signaling in prostate cancer.
Ding M; Jiang CY; Zhang Y; Zhao J; Han BM; Xia SJ
J Exp Clin Cancer Res; 2020 Feb; 39(1):28. PubMed ID: 32019578
[TBL] [Abstract][Full Text] [Related]
3. Atorvastatin Inhibits Breast Cancer Cells by Downregulating PTEN/AKT Pathway via Promoting Ras Homolog Family Member B (RhoB).
Ma Q; Gao Y; Xu P; Li K; Xu X; Gao J; Qi Y; Xu J; Yang Y; Song W; He X; Liu S; Yuan X; Yin W; He Y; Pan W; Wei L; Zhang J
Biomed Res Int; 2019; 2019():3235021. PubMed ID: 31011573
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic SIRT7 inhibits GATA4 transcriptional activity and activates the Wnt signaling pathway in ovarian cancer.
Li G; Xu W; Li X; Chen M; Shi Y; Wei M; Peng D
Gynecol Oncol; 2023 Apr; 171():39-48. PubMed ID: 36804620
[TBL] [Abstract][Full Text] [Related]
5. Aberrant expression of SETD1A promotes survival and migration of estrogen receptor α-positive breast cancer cells.
Jin ML; Kim YW; Jin HL; Kang H; Lee EK; Stallcup MR; Jeong KW
Int J Cancer; 2018 Dec; 143(11):2871-2883. PubMed ID: 30191958
[TBL] [Abstract][Full Text] [Related]
6. Effect of resveratrol on doxorubicin resistance in breast neoplasm cells by modulating PI3K/Akt signaling pathway.
Chen JM; Bai JY; Yang KX
IUBMB Life; 2018 Jun; 70(6):491-500. PubMed ID: 29637742
[TBL] [Abstract][Full Text] [Related]
7. SIRT7 Exhibits Oncogenic Potential in Human Ovarian Cancer Cells.
Wang HL; Lu RQ; Xie SH; Zheng H; Wen XM; Gao X; Guo L
Asian Pac J Cancer Prev; 2015; 16(8):3573-7. PubMed ID: 25921180
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of RSK4 reverses doxorubicin resistance in human breast cancer cells via PI3K/AKT signalling pathway.
Mei Y; Liao X; Zhu L; Yang H
J Biochem; 2020 Jun; 167(6):603-611. PubMed ID: 31960922
[TBL] [Abstract][Full Text] [Related]
9. Tumor-promoting properties of miR-8084 in breast cancer through enhancing proliferation, suppressing apoptosis and inducing epithelial-mesenchymal transition.
Gao Y; Ma H; Gao C; Lv Y; Chen X; Xu R; Sun M; Liu X; Lu X; Pei X; Li P
J Transl Med; 2018 Feb; 16(1):38. PubMed ID: 29471858
[TBL] [Abstract][Full Text] [Related]
10. miRNA-205 targets VEGFA and FGF2 and regulates resistance to chemotherapeutics in breast cancer.
Hu Y; Qiu Y; Yagüe E; Ji W; Liu J; Zhang J
Cell Death Dis; 2016 Jun; 7(6):e2291. PubMed ID: 27362808
[TBL] [Abstract][Full Text] [Related]
11. Increased NHE1 expression is targeted by specific inhibitor cariporide to sensitize resistant breast cancer cells to doxorubicin in vitro and in vivo.
Chen Q; Liu Y; Zhu XL; Feng F; Yang H; Xu W
BMC Cancer; 2019 Mar; 19(1):211. PubMed ID: 30849956
[TBL] [Abstract][Full Text] [Related]
12. Identification of 2,4-dihydroxy-5-pyrimidinyl imidothiocarbomate as a novel inhibitor to Y box binding protein-1 (YB-1) and its therapeutic actions against breast cancer.
Gunasekaran VP; Nishi K; Sivakumar D; Sivaraman T; Mathan G
Eur J Pharm Sci; 2018 Apr; 116():2-14. PubMed ID: 28916481
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-3666-induced suppression of SIRT7 inhibits the growth of non-small cell lung cancer cells.
Shi H; Ji Y; Zhang D; Liu Y; Fang P
Oncol Rep; 2016 Nov; 36(5):3051-3057. PubMed ID: 27599551
[TBL] [Abstract][Full Text] [Related]
14. Evodiamine induces apoptosis and inhibits metastasis in MDA‑MB-231 human breast cancer cells in vitro and in vivo.
Du J; Wang XF; Zhou QM; Zhang TL; Lu YY; Zhang H; Su SB
Oncol Rep; 2013 Aug; 30(2):685-94. PubMed ID: 23708383
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-340 inhibits the growth and invasion of angiosarcoma cells by targeting SIRT7.
Wang X; Song Y
Biomed Pharmacother; 2018 Jul; 103():1061-1068. PubMed ID: 29710664
[TBL] [Abstract][Full Text] [Related]
16. miRNA-192-5p impacts the sensitivity of breast cancer cells to doxorubicin via targeting peptidylprolyl isomerase A.
Zhang Y; He Y; Lu LL; Zhou ZY; Wan NB; Li GP; He X; Deng HW
Kaohsiung J Med Sci; 2019 Jan; 35(1):17-23. PubMed ID: 30844143
[TBL] [Abstract][Full Text] [Related]
17. Sirtuin7 has an oncogenic potential via promoting the growth of cholangiocarcinoma cells.
Li W; Sun Z; Chen C; Wang L; Geng Z; Tao J
Biomed Pharmacother; 2018 Apr; 100():257-266. PubMed ID: 29438839
[TBL] [Abstract][Full Text] [Related]
18. SIRT7 promotes thyroid tumorigenesis through phosphorylation and activation of Akt and p70S6K1 via DBC1/SIRT1 axis.
Li H; Tian Z; Qu Y; Yang Q; Guan H; Shi B; Ji M; Hou P
Oncogene; 2019 Jan; 38(3):345-359. PubMed ID: 30093629
[TBL] [Abstract][Full Text] [Related]
19. Sirtuin 7 promotes cellular survival following genomic stress by attenuation of DNA damage, SAPK activation and p53 response.
Kiran S; Oddi V; Ramakrishna G
Exp Cell Res; 2015 Feb; 331(1):123-141. PubMed ID: 25445786
[TBL] [Abstract][Full Text] [Related]
20. SIRT7 antagonizes TGF-β signaling and inhibits breast cancer metastasis.
Tang X; Shi L; Xie N; Liu Z; Qian M; Meng F; Xu Q; Zhou M; Cao X; Zhu WG; Liu B
Nat Commun; 2017 Aug; 8(1):318. PubMed ID: 28827661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
